Navigation Links
Lifeline Biotechnologies Receives Patent for Methods to Collect and Analyze Breast Thermal Data to Determine Suspect Conditions

RENO, Nev., Sept. 4, 2012 /PRNewswire/ -- Lifeline Biotechnologies, Inc. (OTC Market: LLBO)  announces the award of US Patent #8,226,572 B2 for  Methods for Collecting and Analyzing Thermal Data Based on Breast Surface Temperature to  Determine Suspect Conditions.

"This Methods patent adds to our core intellectual property along with the device patent we received this past May and for our previously FDA approved 510(k) medical device" says Jim Holmes, Chairman/CEO.   "Our basis for originally applying for the three software patents was as a result of the software technical work completed by world renowned pattern recognition specialists we engaged at Nanyang Technological University, Singapore.  Once they had modified and improved our technology capabilities to achieve acceptable and competitive accuracy, sensitivity (false positive) and specificity (false negative) utilizing our patient data, we were convinced our processes were patentable.  This novel and exciting technology holds the potential to change the way early breast tissue abnormalities and breast cancers are detected" concluded Holmes.

First Warning Systems, Lifeline Biotechnologies' exclusive licensee, is currently updating the patient data collection device and its interpretive software to complete the product package in preparation for market entry.  First Warning is conducting a funding round.  See for more information.

About First Warning Systems

First Warning Systems, (FWS) founded in 2008, is based in Reno, NV.  FWS' principal shareholder is Lifeline Biotechnologies, Inc.  Lifeline has licensed FWS with the worldwide exclusive right for  development, manufacturing, marketing and commercialization of its intellectual property.  The product  is a device and process that detects breast tissue abnormalities.  Many of these tissue abnormalities will develop into breast diseases, some of which will be breast cancers.  The FWS process does not involve compression or radiation and is noninvasive. Three clinical trials with over 650 participants have achieved proof of concept and superior outcomes when compared to other protocols.  FWS is planning a final, limited clinical trial and a 510k device classification to validate the fourth generation of the FWS product. FWS is preparing to apply for a Euro CE Mark to market in the UK, EU and Russian markets. See FWS' video, "Breast Cancer Tumor Progression" at  

About Lifeline Biotechnologies

Lifeline Biotechnologies, Inc. (OTC Market: LLBO) founded in 1994 is based in Reno, NV.  LLBO has invested over $10M in a device and process for early detection of breast tissue abnormalities some of which are cancerous or pre-cancer.  Three "Proof of Concept" clinical trials of over 650 women have been completed and three patents (one hardware, two software) have been awarded.

Lifeline's efforts continue to have DTC remove the chill and allow trading to resume.

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, the ability to obtain financing, successful development of the Company's product or market acceptance of the product and regulatory and shareholder approval for anticipated actions.

For more information, contact:   Jim Holmes, CEO 775-852-3222     Email:

SOURCE Lifeline Biotechnologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Leading Scientists to Debate Views on Rejuvenation Biotechnologies
2. UCSB professor receives award for graphene electronics research
3. Watsons Generic Yaz(R) Receives FDA Approval
4. Quanterix Receives Funding From the Department of Homeland Security to Develop Test for Botulinum Toxin
5. Life Technologies Ion Personal Genome Machine Receives San Diegos CONNECT Most Innovative New Product Award
6. MacroGenics Receives Milestone Payment as Part of Its Global DART™ Alliance with Boehringer Ingelheim
7. Intimate Bridge 2 Conception, Inc. Receives $4.3M
8. Pacific Meso Center Receives Generous Donation to First Free-Standing Mesothelioma Research Laboratory in Los Angeles
9. BioNeutral Group Receives $400,000 in Equity Financing
10. Amsterdam Molecular Therapeutics Receives US Orphan Designation for Hemophilia B Gene Therapy
11. Arcion Receives Notice of Allowance for US Patent for Novel Topical Lidocaine Formulation for Pain
Post Your Comments:
(Date:10/11/2017)... ... 11, 2017 , ... Singh Biotechnology today announced that the ... its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) B VHH13 single ... the cell membrane and bind intracellular STAT3 and inhibit its function. Dysregulation of ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give it exclusive ... a technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). ...
(Date:10/10/2017)... , ... October 10, 2017 , ... Dr. Bob Harman, ... his local San Diego Rotary Club. The event entitled “Stem Cells ... and had 300+ attendees. Dr. Harman, DVM, MPVM was joined by two human ...
(Date:10/10/2017)... , Oct. 10, 2017 SomaGenics announced ... the NIH to develop RealSeq®-SC (Single Cell), expected to ... profiling small RNAs (including microRNAs) from single cells using ... highlights the need to accelerate development of approaches to ... "New techniques for measuring levels of ...
Breaking Biology Technology:
(Date:4/5/2017)... 5, 2017  The Allen Institute for Cell Science ... a one-of-a-kind portal and dynamic digital window into the ... the first application of deep learning to create predictive ... lines and a growing suite of powerful tools. The ... and future publicly available resources created and shared by ...
(Date:4/3/2017)... WASHINGTON , April 3, 2017 /PRNewswire-USNewswire/ ... single-cell precision engineering platform, detected a statistically ... cell product prior to treatment and objective ... highlight the potential to predict whether cancer ... prior to treatment, as well as to ...
(Date:3/29/2017)... -- higi, the health IT company that operates the largest ... , today announced a Series B investment from BlueCross ... new investment and acquisition accelerates higi,s strategy to create ... health activities through the collection and workflow integration of ... and secures data today on behalf of over 36 ...
Breaking Biology News(10 mins):